Key Highlights

  • Adial Pharmaceuticals completed its Azora Therapeutics acquisition.
  • The company is shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis.
  • Adial closed the first $32 million Tranche of up to $64 million in financing.
  • Q2 cash rose to $28.7 million, with runway into the second half of 2027.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) completed its Acquisition of Azora Therapeutics, shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis, while closing the first $32 million tranche of up to $64 million in financing.

What Happened

Q2 cash rose to $28.7 million, with runway extending into the second half of 2027, though net loss widened to $52.0 million, mainly from a non-cash $46.2 million acquired in-process Research and Development charge tied to the acquisition.

Market Reaction

The disclosed information does not include stock price or trading data for Adial Pharmaceuticals following the completed acquisition.

Outlook

Continued clinical advancement of AT177 in ulcerative colitis, supported by the extended cash runway into the second half of 2027, is likely to remain the key Factor shaping sentiment toward Adial Pharmaceuticals' stock going forward.